MediWound Reports BARDA Contract Award to Vericel for NexoBrid® Valued at up to $197 Million

Stock Information for Vascular Biogenics Ltd.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Vascular Biogenics Ltd.

MediWound Files Annual Report on Form 20-F
MediWound Reports Fourth Quarter and Full Year 2025 Financial Results
MediWound to Report Fourth Quarter and Full Year 2025 Financial Results
MediWound to Present at Upcoming Investor Conferences
MediWound Provides Corporate Update and Financial Outlook Ahead of the J.P. Morgan Healthcare Conference
MediWound Reports New Clinical Data Demonstrating NexoBrid®'s Effectiveness in Preventing Traumatic Tattoos After Abrasion and Blast Injuries
MediWound Reports Third Quarter 2025 Financial Results and Provides Corporate Update
MediWound to Report Third Quarter 2025 Financial Results

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.